More COVID-19 Headwinds In 2021 For GlaxoSmithKline
Company Sacrificing Profits To Invest In R&D
Executive Summary
The UK-headquartered company is in transition, investing heavily in biopharma R&D and preparing to spin out its consumer division.
You may also be interested in...
After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines
After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.
GSK To Address Multiple Myeloma With First-In-Class Blenrep In EU
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports